Literature DB >> 14602716

The annealing mechanism of HIV-1 reverse transcription primer onto the viral genome.

Carine Tisné1, Bernard P Roques, Frédéric Dardel.   

Abstract

Reverse transcription of human immunodeficiency virus-1 viral RNA uses human tRNA(3)(Lys) as a primer. The first step of viral replication is, thus, the annealing of the primer tRNA onto the primer binding site located in the 5' leader region of the viral RNA. This involves large rearrangements of both RNA structures and requires the chaperone activity of the viral nucleocapsid protein. We have developed a novel approach to analyze dynamically such RNA refolding events using heteronuclear NMR spectroscopy of mixtures of (15)N-labeled and unlabeled large RNA fragments (up to 50 kDa). We have thus been able to characterize the detailed mechanisms of both heat- and nucleocapsid-mediated annealing and to identify previously unknown key steps. The role played by the nucleocapsid is 2-fold; it facilitates strand exchange at the level of the tRNA acceptor stem, presumably via its basic N- and C-terminal extensions, and it unlocks the highly stable tertiary interactions at the level of the T Psi C loop, most likely by specific interactions involving its two zinc knuckles.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14602716     DOI: 10.1074/jbc.M310368200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  Characterization of the inhibition mechanism of HIV-1 nucleocapsid protein chaperone activities by methylated oligoribonucleotides.

Authors:  Sergiy V Avilov; Christian Boudier; Marina Gottikh; Jean-Luc Darlix; Yves Mély
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

Review 2.  Role of HIV-1 nucleocapsid protein in HIV-1 reverse transcription.

Authors:  Judith G Levin; Mithun Mitra; Anjali Mascarenhas; Karin Musier-Forsyth
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

3.  An intermolecular base triple as the basis of ligand specificity and affinity in the guanine- and adenine-sensing riboswitch RNAs.

Authors:  Jonas Noeske; Christian Richter; Marc A Grundl; Hamid R Nasiri; Harald Schwalbe; Jens Wöhnert
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-21       Impact factor: 11.205

4.  Characterization of RNA binding and chaperoning activities of HIV-1 Vif protein. Importance of the C-terminal unstructured tail.

Authors:  Dona Sleiman; Serena Bernacchi; Santiago Xavier Guerrero; Franck Brachet; Valéry Larue; Jean-Christophe Paillart; Carine Tisne
Journal:  RNA Biol       Date:  2014-07-22       Impact factor: 4.652

5.  Influence of L-lysine amino acid on the HIV-1 RNA replication in vitro.

Authors:  Evgeny Vlad Butorov
Journal:  Antivir Chem Chemother       Date:  2015-02

6.  Synthetic tRNALys,3 as the replication primer for the HIV-1HXB2 and HIV-1Mal genomes.

Authors:  Jennifer T Miller; Anastasia Khvorova; Stephen A Scaringe; Stuart F J Le Grice
Journal:  Nucleic Acids Res       Date:  2004-09-01       Impact factor: 16.971

7.  Effect of Mg(2+) and Na(+) on the nucleic acid chaperone activity of HIV-1 nucleocapsid protein: implications for reverse transcription.

Authors:  My-Nuong Vo; George Barany; Ioulia Rouzina; Karin Musier-Forsyth
Journal:  J Mol Biol       Date:  2009-01-06       Impact factor: 5.469

8.  Co-expression of RNA-protein complexes in Escherichia coli and applications to RNA biology.

Authors:  Luc Ponchon; Marjorie Catala; Bili Seijo; Marguerite El Khouri; Frédéric Dardel; Sylvie Nonin-Lecomte; Carine Tisné
Journal:  Nucleic Acids Res       Date:  2013-06-26       Impact factor: 16.971

9.  Initiation of HIV Reverse Transcription.

Authors:  Catherine Isel; Chantal Ehresmann; Roland Marquet
Journal:  Viruses       Date:  2010-01-18       Impact factor: 5.818

10.  The Interaction between tRNA(Lys) 3 and the primer activation signal deciphered by NMR spectroscopy.

Authors:  Dona Sleiman; Pierre Barraud; Franck Brachet; Carine Tisne
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.